Live
NIFTY 5025,291.1▲ 0.58%
SENSEX82,104.79▲ 0.63%
BANK NIFTY61,575.9▲ 0.89%
NIFTY IT31,941.05▲ 0.03%
NIFTY MIDCAP17,774.15▼ 0.58%
INDIA VIX15.68▲ 1.15%
RELIANCE1,344.8▲ 0.38%
TCS2,405▼ 0.10%
HDFCBANK816.5▲ 1.55%
INFY1,145.1▲ 0.32%
ICICIBANK1,585▲ 0.09%
SBIN1,090.5▲ 0.97%
BHARTIARTL2,153.5▲ 2.26%
ITC295.1▲ 3.54%
LT4,140▼ 0.09%
AXISBANK1,342.4▲ 0.86%
KOTAKBANK494.2▲ 1.16%
HINDUNILVR2,000.3▲ 0.37%
Gold (24K)3,861.9▼ 0.63%
Silver46.85▼ 4.44%
Copper6.04▼ 0.67%
Crude Oil (Brent)93.48▼ 2.46%
Natural Gas3.13▼ 2.94%
USD/INR93.91▼ 0.13%
Bitcoin64,557.8▼ 1.14%
Ethereum1,821.07▼ 0.79%
Solana70.95▼ 2.38%
BNB589.26▼ 1.13%
XRP0.95▼ 2.06%
Cardano0.15▲ 1.94%
Dogecoin0.06▲ 1.21%
NIFTY 5025,291.1▲ 0.58%
SENSEX82,104.79▲ 0.63%
BANK NIFTY61,575.9▲ 0.89%
NIFTY IT31,941.05▲ 0.03%
NIFTY MIDCAP17,774.15▼ 0.58%
INDIA VIX15.68▲ 1.15%
RELIANCE1,344.8▲ 0.38%
TCS2,405▼ 0.10%
HDFCBANK816.5▲ 1.55%
INFY1,145.1▲ 0.32%
ICICIBANK1,585▲ 0.09%
SBIN1,090.5▲ 0.97%
BHARTIARTL2,153.5▲ 2.26%
ITC295.1▲ 3.54%
LT4,140▼ 0.09%
AXISBANK1,342.4▲ 0.86%
KOTAKBANK494.2▲ 1.16%
HINDUNILVR2,000.3▲ 0.37%
Gold (24K)3,861.9▼ 0.63%
Silver46.85▼ 4.44%
Copper6.04▼ 0.67%
Crude Oil (Brent)93.48▼ 2.46%
Natural Gas3.13▼ 2.94%
USD/INR93.91▼ 0.13%
Bitcoin64,557.8▼ 1.14%
Ethereum1,821.07▼ 0.79%
Solana70.95▼ 2.38%
BNB589.26▼ 1.13%
XRP0.95▼ 2.06%
Cardano0.15▲ 1.94%
Dogecoin0.06▲ 1.21%
MARKETS 53m ago

US stocks: Summit shares drop after US FDA declines to approve lung cancer drug

Economic Times Markets
Published 16 Nov 2026, 03:48 pm IST
US stocks: Summit shares drop after US FDA declines to approve lung cancer drugAgencies

The regulator on Sunday cited the drug's failure to achieve statistically significant overall survival benefit in a late-stage study that was part of Summit's application.

Follow-up data reported last year also pointed to a greater survival benefit in Chinese patients than those from North America and Europe, although Summit later submitted statistically significant overall survival results from a longer follow-up with consistent improvement across Western and Asian populations.

The FDA's decision sets a "meaningful regulatory precedent" for the drug class, with potential implications for similar drugs being developed by Bristol Myers Squibb, BioNTech , Pfizer, Merck and AbbVie, said BMO Capital analyst Evan Seigerman.

Ivonescimab targets proteins PD-1 and VEGF, which help tumors evade the immune system and spread.

Summit's shares were down 14% at $12.16 in morning trading.

Summit had sought approval for ivonescimab, in combination with chemotherapy, for previously treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations, which account for about 10% to 15% of US cases.

Investors now await data due later this year from a separate global late-stage trial comparing ivonescimab against Merck's blockbuster Keytruda as a first-line treatment for NSCLC.

"I'm still encouraged by the PD-(L)1/VEGF class," with first-line data due for ivonescimab, Bristol Myers and BioNTech's pumitamig, and others, said Adam Schoenfeld, a thoracic oncologist at Memorial Sloan Kettering Cancer Center.

"These therapies could substantially change practice for patients with lung cancer whose tumors do not have an EGFR mutation," Schoenfeld added.

The FDA decision does not alter ivonescimab's prospects in first-line NSCLC, "the substantially larger and more important commercial opportunity," TD Cowen analysts said.

Summit acquired rights to the drug in the US, Canada, Europe and Japan from China's Akeso in 2022.

Originally reported by Economic Times Markets.Source: economictimes.indiatimes.com